SUMMARY

The Molecular Oncology Group’s mission is to apply state-of-the-art tissue-based technologies to basic, translational, and clinical research with a clear focus on developing and validating novel tumor biomarkers for precision cancer medicine. As one of VHIO´s Core Facilities, we currently provide support to more than 160 clinical trials conducted at Vall d’Hebron, representing ~70% of all trials open in our institution. Our activities relating to clinical trials range from the coordination of sample collection and biorepository, developing and running multiple assays for real-time patient inclusion, as well as pharmacodynamic monitoring and dose finding.

In 2014, our laboratory successfully maintained the prestigious ISO15189 quality accreditation for running tissue-based analyses on clinical samples. During this year, we have performed over 2700 molecular determinations on samples for patient inclusion into clinical trials and over 14,000 tests to support basic and translation research programs, with a ~40% overall increase in testing activity as compared to 2013. We have also been the central laboratory for 8 national and international studies.

PUBLICATIONS